C.L. de Groot-Eckhardt MD PhD publications

foto

Publications MD PhD C.L. de Groot-Eckhardt

Positions
Other Academic Staff, Medical Specialist
Main activities
Patient care
Specialisation
Resident (AGIKO), Pediatrics, Emma Children's Hospital, Amsterdam
Focus of research

Hemophilia, pediatric hematology, bleeding disorders

2020

  • van Velzen Alice S., Eckhardt Corien L., Peters Marjolein, Oldenburg Johannes, Cnossen Marjon, Liesner Ri, Morfini Massimo, Castaman Giancarlo, McRae Simon, van der Bom Johanna G., Fijnvandraat Karin Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study British journal of haematology 2020;189 (6):1182-1191 [PubMed]
  • Abdi Amal, Kloosterman Fabienne R., Eckhardt Corien L., Male Christoph, Castaman Giancarlo, Fischer Kathelijn, Beckers Erik A. M., Kruip Marieke J. H. A., Peerlinck Kathelijne, Mancuso Maria Elisa, Santoro Cristina, Hay Charles R., Platokouki Helen, van der Bom Johanna G., Gouw Samantha C., Fijnvandraat Karin, Hart Dan P. The factor VIII treatment history of non-severe hemophilia A Journal of thrombosis and haemostasis 2020;18 (12):3203-3210 [PubMed]

2017

  • van Velzen A. S., Eckhardt C. L., Peters M., Leebeek F. W. G., Escuriola-Ettingshausen C., Hermans C., Keenan R., Astermark J., Male C., Peerlinck K., le Cessie S., van der Bom J. G., Fijnvandraat K. Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study Journal of thrombosis and haemostasis 2017;15 (7):1422-1429 [PubMed]
  • Loomans J. I., Eckhardt C. L., Reitter-Pfoertner S. E., Holmström M., van Gorkom B. Laros, Leebeek F. W. G., Santoro C., Haya S., Meijer K., Nijziel M. R., van der Bom J. G., Fijnvandraat K. Mortality caused by intracranial bleeding in non-severe hemophilia A patients Journal of thrombosis and haemostasis 2017;15 (6):1115-1122 [PubMed]
  • Loomans J. I., van Velzen A. S., Eckhardt C. L., Peters M., Mäkipernaa A., Holmstrom M., Brons P. P., Dors N., Haya S., Voorberg J., van der Bom J. G., Fijnvandraat K. Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations Journal of thrombosis and haemostasis 2017;15 (2):246-254 [PubMed]

2016

  • Eckhardt C. L., van Velzen A. S., Fijnvandraat C. J., van der Bom J. G. Dissecting intensive treatment as risk factor for inhibitor development in haemophilia Haemophilia 2016;22 (3):e241-e244 [PubMed]
  • van Velzen Alice S., Eckhardt Corien L., Streefkerk Nina, Peters Marjolein, Hart Daniel P., Hamulyak Karly, Klamroth Robert, Meijer Karina, Nijziel Marten, Schinco Piercarla, Yee Thynn T., van der Bom Johanna G., Fijnvandraat Karin, Kamphuisen P. W., van der Bom J. G., Peerlinck K., Oldenburg J., Hay C. R. M., Santagostino E., Astermark J., Loomans J. L., van Eijkelenburg A., Jansen A. J., Kruijt C. C., van Tienoven B., van Baar A. C. G., Corten I. W., Bultje A. C., Visser G. R., Meijer K., Nijziel M., Dors N., Hamulyak K., Brons P. P., Laros-van Gorkom B. A. P., van Heerde W. L., Leebeek F. W. G., Kruip M., Cnossen M. H., Mauser-Bunschoten E. P., Fischer K., Smiers F. J., Hermans C., Schwaab R., Siegmund B., Klamroth R., Escuriola-Ettingshausen C., Königs C., Petrini P., Holmström M. The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors Thrombosis and haemostasis 2016;115 (3):543-550 [PubMed]

2015

  • Eckhardt C. L., Loomans J. I., van Velzen A. S., Peters M., Mauser-Bunschoten E. P., Schwaab R., Mazzucconi M. G., Tagliaferri A., Siegmund B., Reitter-Pfoertner S. E., van der Bom J. G., Fijnvandraat K., Kamphuisen P. W., Peerlinck K., Oldenburg J., Santagostino E., Astermark J., Streefkerk N., Loomans J. L., van Eijkelenburg A., Jansen A. J., Kruijt C. C., van Tienoven B., van Baar A. C. G., Corten I. W., Meijer K., Nijziel M. R., Dors N., Hamulyak K., Beckers E., Brons P. P., Laros-van Gorkom B. A. P., van Heerde W. L., Leebeek F., Kruip M., Cnossen M. H., Mauser-Bunschoten E., Fischer K., Smiers F. J., Hermans C., Klamroth R., Escuriola-Ettingshausen C., Königs C., Petrini P., Holmström M., Mäkipernaa A., Male C., Pabinger I., Keenan R. D., Liesner R. Inhibitor development and mortality in non-severe hemophilia A Journal of thrombosis and haemostasis 2015;13 (7):1217-1225 [PubMed]
  • van Velzen Alice S., Eckhardt Corien L., Hart Daniel P., Peters Marjolein, Rangarajan Savita, Mancuso Maria Elisa, Smiers Frans J., Khair Kate, Petrini Pia, Jiménez-Yuste Victor, Hay Charles R. M., van der Bom Johanna G., Yee Thynn T., Fijnvandraat Karin Inhibitors in nonsevere haemophilia A: outcome and eradication strategies Thrombosis and haemostasis 2015;114 (1):46-55 [PubMed]

2014

  • Eckhardt C. L. Inhibitor development in nonsevere hemophilia A 2014. 249p. ISBN 9789461087386. [UvA Dissertations Online] University of Amsterdam. (Supervisor: Kuipers T. W.; Co-supervisors: Kamphuisen P. W., Fijnvandraat C. J., Peters M.)
  • Eckhardt C. L., Astermark J., Nagelkerke S. Q., Geissler J., Tanck M. W. T., Peters M., Fijnvandraat K., Kuijpers T. W. The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A Journal of thrombosis and haemostasis 2014;12 (8):1294-1301 [PubMed]

2013

  • Eckhardt Corien L., van Velzen Alice S., Peters Marjolein, Astermark Jan, Brons Paul P., Castaman Giancarlo, Cnossen Marjon H., Dors Natasja, Escuriola-Ettingshausen Carmen, Hamulyak Karly, Hart Daniel P., Hay Charles R. M., Haya Saturnino, van Heerde Waander L., Hermans Cedric, Holmström Margareta, Jimenez-Yuste Victor, Keenan Russell D., Klamroth Robert, Laros-van Gorkom Britta A. P., Leebeek Frank W. G., Liesner Ri, Mäkipernaa Anne, Male Christoph, Mauser-Bunschoten Evelien, Mazzucconi Maria G., McRae Simon, Meijer Karina, Mitchell Michael, Morfini Massimo, Nijziel Marten, Oldenburg Johannes, Peerlinck Kathelijne, Petrini Pia, Platokouki Helena, Reitter-Pfoertner Sylvia E., Santagostino Elena, Schinco Piercarla, Smiers Frans J., Siegmund Berthold, Tagliaferri Annarita, Yee Thynn T., Kamphuisen Pieter Willem, van der Bom Johanna G., Fijnvandraat Karin Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A Blood 2013;122 (11):1954-1962 [PubMed]

2012

  • Eckhardt Corien L., Mauser-Bunschoten Evelien P., Peters Marjolein, Leebeek Frank W. G., van der Meer Felix J. M., Fijnvandraat Karin Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands British journal of haematology 2012;157 (6):747-752 [PubMed]

2011

  • Eckhardt C. L., van der Bom J. G., van der Naald M., Peters M., Kamphuisen P. W., Fijnvandraat K. Surgery and inhibitor development in hemophilia A: a systematic review Journal of thrombosis and haemostasis 2011;9 (10):1948-1958 [PubMed]

2009

  • Eckhardt Corien L., Kamphuisen Pieter W., Fijnvandraat Karin Inhibitors of factor VIII in hemophilia New England journal of medicine 2009;361 (3):309; author reply 310 [PubMed]
  • Eckhardt C. L., Menke L. A., van Ommen C. H., van der Lee J. H., Geskus R. B., Kamphuisen P. W., Peters M., Fijnvandraat K. Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A Journal of thrombosis and haemostasis 2009;7 (6):930-937 [PubMed]
  • Eckhardt C. L., Menke L. M., van Ommen C. H., van der Lee J. H., Geskus R. B., Kamphuisen P. W., Peters M., Fijnvandraat K. New insights in the cause of inhibitor development in hemophilia A: the Arg593->Cys mutation and high dose of factor VIII may be the culprits. Pediatric clinics Amsterdam 2009;20 (2):8-10